What is Parabolic Drugs share price return in the past 10 years?

Parabolic Drugs Ltd share price has declined -17% annually (CAGR) over the past ten years.

Parabolic Drugs Ltd - Stock Valuation and Financial Performance

Name: Parabolic Drugs
Brand: Parabolic Drugs

BSE: 533211 | NSE: PARABDRUGS | Pharmaceuticals & Drugs | Small Cap

Place order

DeciZen - make an informed investing decision on Parabolic Drugs

Based on:

Data

M-Cap below 100cr DeciZen not available

Parabolic Drugs stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

35.3 Cr.

52-wk low:

5.7

52-wk high:

5.7

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

The key valuation ratios of Parabolic Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is a good buy now?

No data found

10 Year X-Ray of Parabolic Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	TTM
ROCE % ⓘ	14%	13.9%	11.3%	10.5%	-8.8%	-7.7%	-34.7%	-75.3%	-41.9%	-30.8%	-
Value Creation Index ⓘ	0	-0	-0.2	-0.3	-1.6	-1.6	NA	NA	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	395	514	620	924	766	438	232	75.6	73.7	72.6	0
Sales YoY Gr.	-	30.2%	20.6%	49.1%	-17.2%	-42.8%	-47.1%	-67.4%	-2.5%	-1.5%	-
Adj EPS ⓘ	7.5	10.9	8.4	8.3	-22.9	-22.4	-61.3	-76.1	-17.4	-9.2	-3.2
YoY Gr.	-	45.9%	-23.1%	-1.4%	-376.4%	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	25	32.5	61.2	69.2	17.2	3.1	-50.6	-121.8	-134.2	-141.3	-151.7
Adj Net Profit ⓘ	24.2	40.8	52.1	51.3	-142	-139	-379	-471	-108	-56.9	-20
Cash Flow from Ops. ⓘ	-38.3	-30.9	2.5	207	-111	27.9	-3.9	89.6	1.7	3	-
Debt/CF from Ops. ⓘ	-6.9	-13.6	186.5	2.7	-7	30.1	-242.8	10.9	593.3	326.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-17.2%	-37.6%	-32.1%	-1.5%
Adj EPS ⓘ	-202.3%	NA	NA	NA
BVPSⓘ	-221.2%	-252.4%	NA	NA
Share Price	-17%	-9%	-43.1%	-81.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	TTM
Return on Equity % ⓘ	23.7	28.7	19.4	12.7	-38.9	-57.3	5767.8	107.4	14.6	7	2.2
Op. Profit Mgn % ⓘ	15.2	18	18.1	17	-14.6	-29.9	-55.1	-437.9	-104.1	-39	NAN
Net Profit Mgn % ⓘ	6.1	7.9	8.4	5.6	-18.5	-31.7	-163.6	-623.4	-146	-78.4	-INF
Debt to Equity ⓘ	2.5	3.5	1.3	1.3	7.3	43.6	-3.1	-1.3	-1.2	-1.1	-
Working Cap Days ⓘ	239	268	329	297	327	462	757	1,282	647	484	0
Cash Conv. Cycle ⓘ	173	165	189	125	168	276	535	1,038	214	5	0

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Parabolic Drugs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-3.2	-9.3
TTM Sales (₹ Cr.)	0	73.2
BVPS (₹.) ⓘ	-151.7	-142.8
Reserves (₹ Cr.) ⓘ	-1,000	-943
P/BV ⓘ	-0.04	-0.04
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	5.70 / 5.70
All Time Low / High (₹)	0.59 / 79.00
Market Cap (₹ Cr.)	35.3
Equity (₹ Cr.)	61.9
Face Value (₹)	10
Industry PE ⓘ	47.6

Management X-Ray of Parabolic Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

96.71

* Pledged shares as % of Promoter's holding (%)

Valuation of Parabolic Drugs

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Parabolic Drugs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18
Sales	394.92	514.01	619.84	924.34	765.68	437.92	231.78	75.60	73.72	72.60
Operating Expenses ⓘ	335.09	430.89	508.04	766.99	877.24	568.65	359.51	426.49	151.07	101.11
Manufacturing Costs	18.25	23.99	25.02	28.63	26.37	28.83	24.49	15.06	13.30	10
Material Costs	291.73	364.24	447.75	692.62	766.64	367.91	255.55	328.02	91.88	63.42
Employee Cost	10.83	13.90	16.93	22.52	21.59	18.55	17.01	10.68	8.47	9.30
Other Costs ⓘ	14.29	28.75	18.34	23.23	62.65	153.36	62.46	72.74	37.42	18.39
Operating Profit ⓘ	59.82	83.13	111.80	157.35	-111.56	-130.73	-127.73	-350.90	-77.35	-28.51
Operating Profit Margin (%)	15.1%	16.2%	18.0%	17.0%	-14.6%	-29.9%	-55.1%	-464.0%	-104.0%	-39.3%
Other Income ⓘ	2.02	4.75	15.35	4.08	6.04	12.66	1.24	0.31	4.25	4.11
Interest ⓘ	28.34	38.22	40.76	64.14	72.71	83.07	98.69	107.62	10.07	9.25
Depreciation ⓘ	3.61	5.62	17.70	30.85	16.79	18.88	23.82	22.55	21.85	21.59
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	29.90	44.03	68.68	66.44	-195.02	-220.02	-249	-480.76	-105.02	-55.24
Tax ⓘ	5.73	9.83	16.66	15.23	-55.26	-88.28	130.33	4.43	3.05	1.76
Profit After Tax	24.17	34.20	52.03	51.21	-139.76	-131.73	-379.32	-485.19	-108.07	-57
PAT Margin (%)	6.1%	6.7%	8.4%	5.5%	-18.3%	-30.1%	-163.0%	-641.0%	-146.0%	-78.5%
Adjusted EPS (₹)	7.5	9.2	8.4	8.3	-22.6	-21.3	-61.3	-78.4	-17.5	-9.2
Dividend Payout Ratio (%)	0%	0%	6%	3%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18
Equity and Liabilities
Shareholders Fund	125.05	158.62	379	428.41	288.65	156.92	-222.07	-707.26	-815.33	-872.33
Share Capital ⓘ	35.75	37.25	61.89	61.89	61.89	61.89	61.89	61.89	61.89	61.89
Reserves ⓘ	89.30	121.37	317.11	366.52	226.76	95.03	-283.96	-769.15	-877.22	-934.22
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	264.03	420.69	451.36	522.39	776.65	841.93	957.49	971.74	979.46	984.11
Long Term Debt	264.03	420.69	92.27	145.93	421.79	534.62	563.29	731.53	836.30	836.33
Short Term Debt	0	0	359.10	376.46	354.87	307.31	394.20	240.21	143.17	147.78
Trade Payables	107.52	87.89	177.38	284.19	123.86	189.20	101.91	93.18	105.77	80.87
Others Liabilities ⓘ	13.88	22.98	59.51	79.38	6.64	-65.72	112.81	219.34	223.47	226.29
Total Liabilities ⓘ	510.48	690.18	1,067.25	1,314.38	1,195.81	1,122.32	950.14	577	493.37	418.94
Fixed Assets
Gross Block	105.23	144.10	185.01	219.91	382.25	398.34	485.98	483.45	482.71	481.10
Accumulated Depreciation	8.41	13.84	22.06	32.02	48.71	67.59	90.85	112.26	133.87	154.74
Net Fixed Assetsⓘ	96.82	130.27	162.95	187.89	333.54	330.75	395.13	371.19	348.84	326.37
CWIP ⓘ	19.47	40.63	112.25	187.29	72.29	81.49	6.52	6.52	6.52	6.52
Investmentsⓘ	1.98	1.99	5.67	3.57	6.14	6.14	6.32	6.33	6.33	6.34
Inventories	187.28	240.11	340.65	451.73	351.10	367.59	315.38	40.10	15.25	15.88
Trade Receivables	145.87	193.05	275.16	221.76	138.59	148.98	98.05	70.06	66.96	28.82
Cash Equivalents	13.51	17.61	25.66	34.62	12.09	5.99	3.02	0.64	0.60	0.78
Others Assetsⓘ	45.56	66.53	144.91	227.52	282.06	181.39	125.71	82.17	48.88	34.22
Total Assets ⓘ	510.48	690.18	1,067.25	1,314.38	1,195.81	1,122.32	950.14	577	493.37	418.94

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18
Cash Flow From Operating Activity ⓘ	-38.28	-30.93	2.54	207.09	-110.87	27.94	-3.94	89.58	1.65	3.02
PBT ⓘ	29.90	44.03	68.68	66.44	-195.02	-220.02	-249	-480.76	-105.02	-55.24
Adjustment ⓘ	35.30	48.29	58.46	94.99	124.80	151.15	171.65	174.67	63.39	42.89
Changes in Working Capital ⓘ	-99.71	-115.77	-110.07	58.95	-40.66	69.83	73.4	395.67	43.28	15.38
Tax Paid ⓘ	-3.77	-7.48	-14.54	-13.29	0	26.98	0	0	0	0
Cash Flow From Investing Activity ⓘ	-58.27	-87.44	-180.27	-205.01	-108.42	-29.99	-15.89	1.39	0.50	0.86
Capex	-46.31	-60.23	-112.58	-110.03	-47.44	-25.29	-12.90	1.39	0.50	0.88
Net Investments	-1.35	-0.01	-3.68	2.11	-2.58	0	-0.18	0	0	-0.02
Others ⓘ	-10.60	-27.19	-64.02	-97.09	-58.41	-4.70	-2.81	0	0	0
Cash Flow From Financing Activityⓘ	102.70	122.47	185.99	6.89	196.77	-4.06	16.87	-93.36	-2.19	-3.70
Net Proceeds from Shares ⓘ	26.43	4.02	184.81	0	12.28	13.72	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-28.34	-38.22	-40.76	-64.14	-69.78	-83.07	-98.69	-107.62	-9.91	-8.35
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	104.61	156.66	41.94	71.02	254.26	65.28	115.56	14.26	7.72	4.65
Net Cash Flow ⓘ	6.16	4.10	8.26	8.96	-22.52	-6.11	-2.96	-2.39	-0.03	0.18

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18
Ratios
ROE (%)	33.95	33.92	20.81	12.69	-52.25	-209.38	N/A	N/A	N/A	N/A
ROCE (%)	19.7	18.05	15.69	14.22	-13.02	-15.36	N/A	N/A	N/A	N/A
Asset Turnover Ratio	1.06	0.93	0.77	0.86	0.66	0.39	0.23	0.11	0.14	0.16
PAT to CFO Conversion(x)	-1.58	-0.9	0.05	4.04	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	100	111	126	89	79	116	186	363	339	241
Inventory Days	123	140	156	142	176	289	513	768	137	78
Payable Days	67	98	108	122	97	155	208	109	395	537

Parabolic Drugs Ltd Stock News

Parabolic Drugs Ltd FAQs

What is the share price of Parabolic Drugs?

Company share prices are keep on changing according to the market conditions. The closing price of Parabolic Drugs on 25-Jan-2021 18:59 is ₹1.05.

What is the market cap of Parabolic Drugs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 25-Jan-2021 18:59 the market cap of Parabolic Drugs stood at ₹35.28.

What is the P/E ratio of Parabolic Drugs?

The latest P/E ratio of Parabolic Drugs as of 25-Jan-2021 18:59 is 0.00.

What is the P/B ratio of Parabolic Drugs?

The latest P/B ratio of Parabolic Drugs as of 25-Jan-2021 18:59 is -0.04.

What is the 52-week high and low of Parabolic Drugs?

The 52-week high of Parabolic Drugs is ₹5.70 and the 52-week low is ₹5.70.

What is the TTM revenue of Parabolic Drugs?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Parabolic Drugs is ₹0.00 ( Cr.) .

About Parabolic Drugs Ltd

Parabolic Drugs was incorporated on February 22, 1996 under the Companies Act, 1956, with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. The company is promoted by Pranav Gupta, Vineet Gupta, PNG Trading Private Limited (PNG) and Parabolic Infrastructure Private Limited (PIPL).

At present, the company is currently own and operate two manufacturing facilities at Derabassi, Punjab, and Panchkula, Haryana. It commenced commercial operations in February 1998 by setting up a unit at Sundhran, Derabassi, to manufacture SSPs. Currently, it has six units at Sundhran, Derabassi, for manufacturing the oral and sterile range of Cephalosporin APIs and intermediates. The facility at Sundhran, Derabassi, is WHO-GMP and ISO-14001 certified.

Parabolic Drugs started its second facility at Panchkula in fiscal year 2005. Currently, the Panchkula facility has two units manufacturing SSPs and API intermediates such as 6-APA. It is also in the process of setting up a custom synthesis and research and development (R&D) centre at Barwala, Haryana, for development and scale-up of new APIs and APIs intermediates in all therapeutic segments, including non-antibiotic products. This facility is expected to commence operations in the last quarter of fiscal year 2010, to focus on providing contract research services to innovator companies.

In addition, the company is in the process of setting up another manufacturing facility at Chachrauli, Derabassi, to manufacture the non-antibiotic range of APIs, which is expected to commence commercial operations in the third quarter of fiscal year 2011.

The companyâ€™s product portfolio presently comprises 42 APIs and seven API intermediates which are marketed and exported domestically in the market. It supplies its products to approximately 45 countries, including regulated markets. It has filed 15 dossiers with the relevant regulatory authorities to increase its penetration in the regulated markets. This includes six DMFs filed with the USFDA, one DMF filed with the Bureau of Pharmaceutical Sciences, Canada and eight dossiers filed with the EDQM, including two for which it has received Certificates of Suitability (CoS) from the EDQM, for supplying Amoxicillin and Flucloxacillin Sodium for the European markets. Currently, it supplies 6-APA from its Panchkula facility for the US markets conforming to the regulations prescribed by the USFDA.

The company has an established R&D setup which comprises chemical and analytical research laboratories at our facility at Sundhran, Derabassi. The companyâ€™s focus is on developing non-infringing processes for new molecules for expansion of its product portfolio, existing process improvements and production cost efficiencies. Its R&D department has led the company to successfully launch additional sterile and oral products over the years. During fiscal year 2010, products such as Ceftazidime, Cefotiam, Ceftizoxime and Cephalothin were launched to further widen its product range.

It has made eight applications for the process patents, of which seven patent applications have been filed with the Indian Patent Office, and one international process patent for manufacturing Cefuroxime Axetil filed under the PCT.

Business area of the company

The company is presently engaged in the manufacturing, including contract manufacturing, of APIs and API intermediates for the domestic market as well as for exports to international markets, including regulated markets.

Subsidiary of the company

Parabolic Labs: The company was incorporated as a private limited company under the Companies Act, 1956 on November 21, 2007 and received its Certificate for Commencement of business on January 3, 2008.

Parabolic Labs is authorized to engage in the business of manufacturing, buying, selling, repacking C&F agents, manipulating, importing, exporting, distributing and trading in or otherwise dealing in all types of basic drugs, pharmaceuticals, medicines, preparations, compounds, spirits, patent medicines, drugs, mineral waters, 96 chemicals, petrochemicals, etc., to carry on work relating to contract research on drugs manufactured by other manufacturers and to carry on research for the development of new drugs.

Group companies

Pranav Gupta Family Trust (PGFT)
Vineet Gupta Family Trust (VGFT)
Vineet Packaging Industries (VPI)
Jamboree Education (JEPL)
Parabolic Estates (PEPL)
Skyview Infotech (Skyview)

Milestones

1996: Incorporated and received Certificate for Commencement of business
1998: Commencement of commercial production of oral Semi Synthetic Penicillin APIs at Derabassi
1999: Initiated contractual manufacturing services
2003: Entered into export market through direct and third-party exports.
2004: Set up of our regulatory affairs department for the filings of our dossiers
2005: Commenced commercial production from Unit-II at Panchkula and capacity enhanced by 360 TPA
2005: Two dossiers filed in the European Union for CoS
2005: Launch of our first Cephalosporin oral API (Cefixime Trihydrate)
2005: The company was awarded WHO-GMP certificate for Amoxicillin Trihydrate and Flucloxacillin Sodium vide Certificate no.09 & 10 dated October 11, 2004
2006: Commercial operation of new Cephalosporin API plant for Cefuroxime Axetil
2006: USFDA approval for supply of 6-APA into US markets
2007: Raised funding from Alden (formerly Minivet Limited) and Exquisite
2007: Commercial operation of a new plant for manufacturing Sterile Semi Synthetic Penicillin API
2007: Diversification into third and fourth generation Cephalosporin API
2007: Commercial operation of new Cefuroxime Axetil (Amorphous) plant
2008: CoS received from the EDQM for Amoxycillin and Flucloxacillin allowing exports to the European Union
2008: Three dossiers filed in US and European Union
2008: Commercial operation of new multipurpose block-I for Cephalosporins API
2008: Three process patents filed with the Indian Patent Office
2009: Eight dossiers filed in US, Canada and European Union
2009: Raised funding from BTS
2009: Commercial operation of new Cefuroxime Axetil plant with 100 TPA capacity
2009: Launch of Sterile Cephalosporin APIs
2009: Four process patents filed with the Indian Patent Office and one PCT application filed
2010: Received an ISO 14001:2004 Management System Certificate from Det Norske Veritas
2010: Diversified into custom synthesis for innovator companies under CRAMS model